Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 1108 results for infections

  1. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

  2. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    although these don't always work. Infections, including wound infections, vaginal infections and urinary tract...

  3. Behavioural strategies and programmes:- What is the feasibility and effectiveness of specific behavioural strategies and programmes to reduce inappropriate antimicrobial demand and use and to prevent infections occurring and spreading?

    programmes to reduce inappropriate antimicrobial demand and use and to prevent infections occurring and spreading? Any explanatory...

  4. Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

  5. Neonatal infection guidance updated to allow home antibiotic treatment for some babies

    We’ve recommended that newborn babies receiving antibiotics in hospital could potentially switch to oral antibiotics and be cared for at home if they are doing well and responding to treatment.

  6. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  7. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (HTG717)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

  8. Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic accuracy of serial C-reactive protein testing to identify chorioamnionitis in women with P-PROM?

    Recommendation ID NG25/2 Question Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the...

  9. Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (HTG300)

    Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.

  10. Alcohol-use disorders: diagnosis and management of physical complications (CG100)

    This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.

  11. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  12. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

  13. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

  14. Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)

    Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  15. Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?

    could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment? Any...